Is compounded GLP-1 legal in 2026?
As of October 15, 2026, compounded tirzepatide and semaglutide are not FDA-approved, and because FDA's shortage-era grace periods for both ended in 2025, a pharmacy may compound them only for an individual patient whose prescriber documents a clinically significant difference from the approved drug. FDA's September 18, 2026 warning letter to Empower Pharmacy said its tirzepatide-niacinamide and semaglutide-B12 products appeared to be essentially copies. FDA has proposed keeping all three GLP-1s off the 503B bulks list; no final decision had been published. Retatrutide and cagrilintide cannot be compounded at all, FDA says.
Qualification: legality is decided prescription by prescription, so a program being open for business does not prove that every product it sells meets the rule; ask what clinical difference your prescription documents.
Which compounded GLP-1 routes are still legal?
Federal law bars compounders from making drugs that are essentially copies of commercially available FDA-approved products. During the 2022–2025 shortages that bar was relaxed. It applies again now, which leaves one narrow route and closes the others.
| Route | Status | What it requires |
|---|---|---|
| 503A pharmacy, individual prescription | Open, narrowly | prescriber documents a clinically significant difference from the approved drug for that patient |
| 503B outsourcing facility from bulk | Proposed to close | FDA proposed excluding all three GLP-1s from the 503B bulks list; no final decision |
| Copies of Wegovy, Zepbound or Mounjaro | Closed | grace periods ended in 2025; FDA treats “essentially copies” as unlawful, including with added ingredients |
| Retatrutide or cagrilintide | Not allowed | FDA says they cannot be used in compounding under federal law |
| “Research use only” sellers | Not lawful for human use | FDA warning letters of August 24, 2026 |
How did the compounded GLP-1 rules change from 2022 to October 2026?
The early rows come from FDA orders and court decisions we summarised in July 2026 and did not re-read for this update. The 2026 rows were read on October 15, 2026.
| Date | What happened | Why it matters | Source |
|---|---|---|---|
| 2022 | Semaglutide and tirzepatide placed on FDA’s drug shortage list | Shortage status opened the window for compounding copies | carried from July 2026 |
| Oct 2, 2024 / Dec 19, 2024 | FDA declares the tirzepatide shortage resolved, then reaffirms it in a declaratory order | Starts the transition periods for compounders | carried from July 2026 |
| Feb 21, 2025 | FDA removes semaglutide from the shortage list | Starts the semaglutide transition | carried from July 2026 |
| Feb–May 2025 | Grace periods end for 503A pharmacies and 503B outsourcing facilities for both drugs | Routine copies no longer covered; courts upheld FDA in OFA v. FDA | carried from July 2026 |
| Apr 30, 2026 | FDA proposes not to place tirzepatide, semaglutide or liraglutide on the 503B bulks list (91 FR 23431) | Would close the outsourcing-facility route from bulk drug substance | fda.gov |
| Jun 26, 2026 | Comment period extended to July 30, 2026 (91 FR 38719) | Final decision delayed | federalregister.gov |
| Aug 24, 2026 | FDA warning letters to five “research use only” peptide sellers, naming tirzepatide, semaglutide and retatrutide among unapproved new drugs | “Research use only” labels are not a lawful route | fda.gov |
| Sep 18, 2026 (posted Sep 22) | Warning letter 738238 to Empower Pharmacy: tirzepatide-niacinamide and semaglutide-B12 “appear to be essentially copies”; insanitary conditions cited | Adding an ingredient does not by itself make a product lawful | fda.gov |
| Oct 1, 2026 | FDA’s GLP-1 concerns page: retatrutide and cagrilintide cannot be used in compounding; 28-day discard rule for compounded multi-dose GLP-1 vials | Bans two investigational molecules outright | fda.gov |
| Oct 15, 2026 | No final 503B decision found | The 503B proposal is still a proposal | our read of fda.gov and federalregister.gov |
What does the Empower warning letter change?
Some compounded GLP-1 products add an ingredient such as vitamin B12 (cyanocobalamin) or niacinamide. FDA’s September 18, 2026 letter to Empower Pharmacy addressed two such products, finding that they appeared to be essentially copies of the approved drugs, and it cited insanitary conditions. A letter is not a court ruling, but it shows how FDA reads the rule.
What does this mean if you take compounded semaglutide or tirzepatide?
The legal risk falls mostly on pharmacies and sellers. The practical risk for you is continuity and quality: an enforcement action can stop a pharmacy’s supply, and FDA does not review compounded drugs for safety, effectiveness or quality before sale.
Price is part of the picture. The 28 compounded tirzepatide programs in our index publish $86 to $280 a month (median $144), while FDA-approved GLP-1s now start at $149 a month for the Wegovy pill and Foundayo. Eligible Medicare Part D enrollees can pay $50 under the GLP-1 Bridge. Our GLP-1 cost guide compares the pathways.
Compounded versus brand, legally: pros and cons
Pros
- Compounded: lower monthly prices in our index; some programs charge one price at every dose
- Brand: FDA-approved, with trial data and manufacturer quality controls
- NexLife’s plan pages name three state-licensed 503A pharmacies (Lutz, FL; Decatur, AL; Lake Charles, LA)
Cons
- Compounded: legal only for an individual patient with a documented clinical difference
- Compounded: supply can stop if FDA acts against a pharmacy
- NexLife’s microdose and landing pages list five possible pharmacies, including Empower, “or other qualified 503A compounding pharmacies”; ask which one fills your order
What should you ask a compounded GLP-1 provider?
- Which pharmacy fills my prescription, and is it state-licensed in my state?
- Is it a 503A pharmacy or a 503B outsourcing facility? (See 503A vs 503B.)
- What clinically significant difference does my prescription document?
- Does the product contain added ingredients, and why?
- What happens to my treatment and my prepaid months if the pharmacy stops supplying?
Track new FDA actions on our regulatory updates page, and see how sellers disclose pharmacies in our NexLife review.
Frequently asked questions
Is compounded tirzepatide or semaglutide legal in 2026?
As of October 15, 2026, compounded tirzepatide and semaglutide are not FDA-approved, and because FDA's shortage-era grace periods for both ended in 2025, a pharmacy may compound them only for an individual patient whose prescriber documents a clinically significant difference from the approved drug. FDA's September 18, 2026 warning letter to Empower Pharmacy said its tirzepatide-niacinamide and semaglutide-B12 products appeared to be essentially copies. FDA has proposed keeping all three GLP-1s off the 503B bulks list; no final decision had been published. Retatrutide and cagrilintide cannot be compounded at all, FDA says.
Can a pharmacy still compound semaglutide or tirzepatide?
A state-licensed 503A pharmacy may compound them for an individual patient when the prescriber documents a clinically significant difference from the approved drug. Making routine copies of Wegovy, Ozempic, Zepbound or Mounjaro has not been covered since FDA’s grace periods ended in 2025. Adding a vitamin does not settle the question, as FDA’s September 2026 Empower letter shows.
What did FDA say in the Empower Pharmacy warning letter?
FDA’s warning letter 738238, dated September 18, 2026 and posted September 22, told Empower Pharmacy that its compounded tirzepatide with niacinamide and semaglutide with cyanocobalamin appeared to be essentially copies of FDA-approved semaglutide and tirzepatide products. The letter also cited insanitary conditions. It shows FDA does not accept an added ingredient as enough on its own.
Is the 503B route for GLP-1s closed?
Not yet finally. On April 30, 2026, FDA proposed not placing tirzepatide, semaglutide or liraglutide on the 503B bulks list, which outsourcing facilities need to compound from bulk drug substance. The comment period was extended to July 30, 2026. We found no final decision as of October 15, 2026, so check our regulatory updates page.
Can retatrutide be compounded?
No. FDA’s page on unapproved GLP-1 drugs, current as of October 1, 2026, states that retatrutide and cagrilintide cannot be used in compounding under federal law. Retatrutide sold online is typically labelled “research use only”, and FDA named it in its August 24, 2026 warning letters to five such sellers.
What does this mean for my compounded GLP-1 prescription?
The main patient risk is continuity: if a pharmacy is forced to stop, your supply can stop mid-course. Ask your provider which pharmacy fills your prescription, whether it is state-licensed, what clinical difference the prescription documents, and what the plan is if supply is interrupted. Compounded GLP-1s are not FDA-approved.
Sources
- FDA — Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (current as of October 1, 2026) (read October 15, 2026)
- FDA — proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list (April 30, 2026) (read October 15, 2026)
- Federal Register — 91 FR 23431, 503B bulks list proposal (read October 15, 2026)
- Federal Register — 91 FR 38719, comment period extended to July 30, 2026 (read October 15, 2026)
- FDA — warning letter 738238 to Empower Pharmacy (September 18, 2026) (read October 15, 2026)
- FDA — warning letter 735063 to Peptide Partners (August 24, 2026) (read October 15, 2026)
- CMS — Medicare GLP-1 Bridge (read October 15, 2026)
- NexLife — compounded tirzepatide plans (read October 15, 2026)
Every program price on this page comes from the October 15, 2026 rows of our GLP-1 pricing database (CSV and JSON, CC BY 4.0). Spotted an error? Submit a correction.